IFC Holdings’s Myriad Genetics MYGN Stock Holding History

IFC Holdings’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-12,678	Closed	-$434K	–	274
2017 Q4	$434K	Buy	12,678 +533	+4%	+$18K	0.03%	328
2017 Q3	$438K	Buy	+12,145	New	+$346K	0.03%	327

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

IFC Holdings's MYGN Position: Q1 2018 in Review

IFC Holdings sold out of Myriad Genetics (MYGN) in Q1 2018, closing a stake of 12,678 shares — an estimated $434K sold.

IFC Holdings first reported a position in MYGN in Q3 2017 and held it in 2 quarters. The position peaked at $438K in Q3 2017. 260 funds tracked by Wall St. Rank hold MYGN as of Q1 2018.

IFC Holdings reported no remaining Myriad Genetics position as of Q1 2018 after selling out during the quarter.
IFC Holdings sold 12,678 Myriad Genetics shares in Q1 2018, an estimated $434K.
IFC Holdings first reported a position in Myriad Genetics in Q3 2017 and held it in 2 quarters.
IFC Holdings's Myriad Genetics position peaked at $438K in Q3 2017.
260 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2018.

Based on IFC Holdings's 13F filing for Q1 2018.